FDANews
FDAnews Drug Daily Bulletin

NICE Guidance Links Cost-Effectiveness of Osteoporosis Treatments with Fracture Risk

Aug. 15, 2017

New guidance from the UK’s National Institute of Health and Care Excellence links the cost-effectiveness of different bisphosphonate medications for osteoporosis with a patient’s 10-year risk of bone fractures.

NICE recommended beginning treatment with oral alendronic acid, ibandronic acid or risedronate sodium in individuals with at least a 1 percent risk of fracture over a decade. Intravenous ibandronic acid and zoledronic acid is recommended for those with at least a 10 percent risk.

Clinical trial results showed Olumiant plus conventional disease-modifying antirheumatic drugs were more effective than conventional treatments alone for severe RA, according to NICE.

View today's stories